Tag Archives: EU
By Julian Upton | Published: April 4, 2014
A report published yesterday provides recommendations for combating the “significant inequalities” affecting access to quality cancer care in Europe.
By Pharm Exec | Published: April 3, 2014
The European Parliament yesterday voted towards the adoption of the new Clinical Trials Regulation, which removes the legal framework for pharma to not publish its data by stating that information from trial study reports should not be considered commercially confidential.
By Pharm Exec | Published: March 28, 2014
Adrian van den Hoven, Director General of the European Generics Association (EGA), this week called for the removal of barriers to generic medicines across the European Union.
By Reflector | Published: March 10, 2014
The plan to accelerate generic pricing and reimbursement has become another tragic European casualty, writes Brussels correspondent Reflector.
By Pharm Exec | Published: February 21, 2014
Europe’s leading pharma industry bodies — EFPIA, EGA, EuropaBio, AESGP and EUCOPE — have issued a joint statement to express concern about “the increasing financial burden of regulatory costs incurred since the adoption of the pharmacovigilance package in 2010″. Procedural fees such as for pharmacovigilance referrals, they argue, have been significantly increased in the last […]